Barclays PLC Silence Therapeutics PLC Transaction History
Barclays PLC
- $327 Billion
- Q2 2024
A detailed history of Barclays PLC transactions in Silence Therapeutics PLC stock. As of the latest transaction made, Barclays PLC holds 5,570 shares of SLN stock, worth $100,649. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,570
Previous 5,570
-0.0%
Holding current value
$100,649
Previous $120,000
11.67%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding SLN
# of Institutions
70Shares Held
27.1MCall Options Held
0Put Options Held
0-
Tcg Crossover Management, LLC Palo Alto, CA3.3MShares$59.5 Million9.38% of portfolio
-
Artal Group S.A. Luxembourg, N42.78MShares$50.2 Million3.35% of portfolio
-
Lombard Odier Asset Management (Usa) Corp New York, NY2.41MShares$43.5 Million3.46% of portfolio
-
Redmile Group, LLC San Francisco, CA2.01MShares$36.4 Million2.5% of portfolio
-
Logos Global Management LP San Francisco, CA1.48MShares$26.7 Million2.63% of portfolio
About Silence Therapeutics plc
- Ticker SLN
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,888,400
- Market Cap $649M
- Description
- Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated...